6-mo. Min Eff Dose of Flibanserin: 25 v 50 mg Bid v 50 mg hs v Pbo in Younger Women in NA

Completed · Phase 3 · Has a placebo group

Conditions studied: Sexual Dysfunctions, Psychological

In brief

This trial is designed to assess the safety and efficacy of flibanserin in the treatment of premenopausal women with Hypoactive Sexual Desire Disorder (HSDD) that meet standard diagnostic criteria. Efficacy for flibanserin will be assessed vs. a parallel placebo group.

Key facts

Study ID: NCT00360243
Run by: Sprout Pharmaceuticals, Inc
People needed: 1385
Starts: 2006-07-01
Expected to finish: 2008-04-01
Last updated by the study team: 2016-06-27

Who can join

Age: 18 and older, up to 50. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

Women who are 18 years of age and older.
Premenopausal women having regular menstrual periods who have HSDD (decreased sexual desire), generalized acquired type, according to DSM IV-TR criteria.
Patient must meet minimum cut-off scores on questionnaires relating to sexual functioning and sexual distress.
Patients must be willing to try to have sexual activity (e.g., any act involving direct genital stimulation) at least once monthly.
Patients must be willing and able to use an electronic diary on a daily basis (e.g., have access to a working land line telephone for daily data transmissions).
At the Baseline Visit, patients must have complied with eDiary use adequately.
Patients must be in a stable, monogamous, heterosexual relationship that is secure and communicative, for at least 1 year prior to the Screen Visit. The partner is expected to be physically present at least 50% of each month.
Patients must have used a medically acceptable method of contraception for at least 3 months before the Baseline Visit (Visit 2) and continue to use that medically acceptable method of contraception during the trial.
In the investigators opinion, patients must be reliable, honest, compliant, and agree to co-operate with all trial evaluations as well as to be able to perform them.
Patients must be able and willing to give meaningful, written informed consent prior to participation in the trial, in accordance with regulatory requirements. Patients must have sufficient understanding to communicate effectively with the investigator, and be willing to discuss their sexual functioning with the investigative staff.
Patients must have a clinically acceptable Pap smear as read by a cytology facility (no evidence of malignancy or squamous intraepithelial lesions) within 6 months before the Screen Visit.

You may not qualify if…

Patients who have taken any medication noted in the protocols List of Prohibited Medications within 30 days before screening.
Patients whose sexual function was affected (enhanced or worsened) in the investigators opinion by any medication within 30 days before the Screen Visit and anytime prior to the Baseline Visit.
Patients with a history of drug dependence or abuse within the past one year.
Patients with a history of multiple severe reactions (i.e., allergic or oversensitivity to usual doses) to drugs that affect the brain.
Patients with a history of participation in a trial of another investigational medication within one month prior to the Screen Visit, or participation in any previous clinical trial of flibanserin.
Patients who meet accepted diagnostic criteria for sexual disorders that would interfere with improvement in HSDD (sexual aversion, substance-induced sexual problems, urge to live as a man, etc.
Patients who indicate that their sexual partner has inadequately treated sexual problems that could interfere with the patients response to treatment.
Patients who have entered the menopausal transition or menopause or have had a hysterectomy.
Patients with findings at the Screen Visit of infection, inflammation, undue tenderness, or shrinkage (atrophy) of the female organs.
Patients who are breast feeding or have breastfed within the last 6 months prior to the Baseline Visit.
Patients who are pregnant or have been pregnant within the last 6 months prior to the Baseline Visit.

Where it is running

511.70.01040 Boehringer Ingelheim Investigational Site — Mobile, Alabama, United States
511.70.01041 Boehringer Ingelheim Investigational Site — Tucson, Arizona, United States
511.70.01003 Boehringer Ingelheim Investigational Site — Jonesboro, Arkansas, United States
511.70.01070 Boehringer Ingelheim Investigational Site — Carmichael, California, United States
511.70.01026 Boehringer Ingelheim Investigational Site — Redding, California, United States
511.70.01015 Boehringer Ingelheim Investigational Site — San Diego, California, United States
511.70.01014 Boehringer Ingelheim Investigational Site — Stanford, California, United States
511.70.01017 Boehringer Ingelheim Investigational Site — Tarzana, California, United States
511.70.01072 Boehringer Ingelheim Investigational Site — Torrance, California, United States
511.70.01078 Boehringer Ingelheim Investigational Site — Vista, California, United States
511.70.01066 Boehringer Ingelheim Investigational Site — Walnut Creek, California, United States
511.70.01064 Boehringer Ingelheim Investigational Site — Denver, Colorado, United States
511.70.01001 Boehringer Ingelheim Investigational Site — Wheat Ridge, Colorado, United States
511.70.01050 Boehringer Ingelheim Investigational Site — Farmington, Connecticut, United States
511.70.01006 Boehringer Ingelheim Investigational Site — Hartford, Connecticut, United States
511.70.01055 Boehringer Ingelheim Investigational Site — New London, Connecticut, United States
511.70.01024 Boehringer Ingelheim Investigational Site — Aventura, Florida, United States
511.70.01056 Boehringer Ingelheim Investigational Site — Daytona Beach, Florida, United States
511.70.01090 Boehringer Ingelheim Investigational Site — Fort Lauderdale, Florida, United States
511.70.01027 Boehringer Ingelheim Investigational Site — Gainesville, Florida, United States
511.70.01062 Boehringer Ingelheim Investigational Site — New Port Richey, Florida, United States
511.70.01043 Boehringer Ingelheim Investigational Site — Orlando, Florida, United States
511.70.01084 Boehringer Ingelheim Investigational Site — Pembroke Pines, Florida, United States
511.70.01048 Boehringer Ingelheim Investigational Site — St. Petersburg, Florida, United States
511.70.01068 Boehringer Ingelheim Investigational Site — Huntsville, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.